Nanorepro AG Stock
Price
Target price
€1.79
€1.79
-5.660%
-0.11
-5.660%
-
23.08.24 / Tradegate
WKN: 657710 / Name: NanoRepro / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Nanorepro AG Stock
Nanorepro AG took a tumble today and lost -€0.110 (-5.660%).
For the coming years our community has positive and negative things to say abot the Nanorepro AG stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Brand" there were negative voices in the community.
Pros and Cons of Nanorepro AG in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Nanorepro AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Nanorepro AG | -5.660% | -3.514% | -5.556% | -22.391% | -13.350% | -79.553% | 78.500% |
| Heidelberg Pharma AG | -2.940% | -1.235% | -9.091% | -30.233% | -34.783% | -65.217% | 1.266% |
| Vivoryon Therapeutics N.V. | 0.220% | 1.602% | -16.541% | -82.183% | -72.388% | -88.765% | -65.741% |
| Larimar Therapeutics Inc. | -3.500% | 1.471% | -19.767% | 91.667% | 69.118% | -41.026% | -22.213% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-04
The financial statements of NanoRepro, a company operating in the biotechnology and medical research industry, reveal a mixed performance in recent years. It is essential to evaluate the company's financial position by delving into the provided financial statements' key figures and ratios, including its balance sheets, cash flow statements, and income statements over the years.
*Pros: *
Growing total assets: Over the years, NanoRepro has demonstrated a consistent increase in its total assets. From 2019 to 2021, the asset base expanded from €4.8 million to €79.1 million, a remarkable growth trajectory that typically characterizes an expanding company.
